Weight loss drug ETF bets big on Eli Lilly, Novo Nordisk

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments’ GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on … Read more

AstraZeneca to boost revenue, release new medicines by 2030

The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have … Read more

FDA approves Amgen small cell lung cancer treatment

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images The Food and Drug Administration on Thursday approved Amgen‘s therapy for patients with the most deadly form of lung cancer.  The agency cleared the drug, which will be marketed under the name Imdelltra, as a second or later line of treatment … Read more

Amgen could threaten Novo Nordisk, Eli Lilly weight loss drug dominance

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk and Eli Lilly have long dominated the rapidly growing weight loss drug market, but their duopoly is closer than ever to facing a threat from a new rival.  Amgen … Read more

Amgen soars on weight loss drug progress, Novo Nordisk, Eli Lilly slide

Pavlo Gonchar | Lightrocket | Getty Images Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection.  That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, … Read more

Amgen scraps experimental weight loss pill, moves forward with injection

The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is among several drugmakers racing … Read more

Microsoft shares jump 4% after the AI winner delivers in right places

Microsoft delivered picture-perfect earnings after the bell Thursday, calming the market’s brief fears about runaway spending on AI infrastructure without the cloud revenues to show for it. Revenue increased about 17% year over year, to $61.86 billion, beating the Street consensus estimate of $60.8 billion, according to data from LSEG. Earnings per share (EPS) increased … Read more

Johnson & Johnson (JNJ) earnings Q1 2024

An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Tuesday reported first-quarter adjusted earnings that topped Wall Street’s expectations as sales in its medical devices business surged. Meanwhile, the company’s total revenue for the … Read more

Amgen aims to enter weight loss drug market with a new approach

The Amgen logo is displayed outside Amgen headquarters on May 17, 2023 in Thousand Oaks, California. Mario Tama | Getty Images Amgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. The biotech company is testing an injectable … Read more

Nvidia’s Jensen Huang takes page out of Apple playbook to lead AI’s future

When Nvidia CEO Jensen Huang took the stage Monday at the chipmaker’s hyped-up artificial intelligence conference, he joked to the thousands of attendees packed into the arena that this was “not a concert.” In a literal sense, Huang was right. But that didn’t stop him from using his two-hour keynote address to cement Nvidia’s status … Read more